By employing clinically relevant primate models, RxGen enables accurate identification and characterization of toxicity, improve speeds candidate selection, decreases compound attrition, and improves time to market of small molecule therapeutics, biologics, and medical devices.
- Clinical pathology
- Study-specific endpoints
Design and execution
- Acute, subchronic, chronic
- Oral, intravenous, intramuscular, subcutaneous, intraperitoneal, ocular
- Safety pharmacology study design to define endpoints for incorporation into larger follow-on toxicology, kinetic and clinical studies